

# ECONOMICAL ANALYSIS OF TENOFOVIR ALAFENAMIDE VERSUS TENOFOVIR DISOPROXIL




M Camean-Castillo, E. Rios-Sanchez, MD Gil-Sierra, MDP Briceño-Casado, FJ Salmeron-Navas, S. Fenix-Caballero, J Diaz-Navarro, C. Martinez-Diaz, EJ Alegre-DelRey, JM Borrero-Rubio  
*Hospital Universitario Puerto Real, Cádiz.*

## PURPOSE

The objective of the study is to assess the cost of using TAF instead of tenofovir-disoproxil fumarate (TDF) in a public health hospital

## MATERIAL AND METHODS



## RESULTS

**204 Patients**

**Adherence 95%**

The patient cost and its annual potential cost are summarized in the following table

**151 patients → TDF + emtricitabine + elvitegravir**  
**16 patients → TDF + emtricitabine + darunavir/cobicistat**  
**37 patients → TDF + emtricitabine + 3<sup>o</sup> drug**

	Nº patients	Patient cost	Annual cost	Difference
TDF+emtricitabine+elvitegravir	151	560,22€	1.015.118,64€	
TAF+emtricitabine+elvitegravir	151	726€	1.315.512€	300.393,36€
TDF+emtricitabine+darunavir/cobicistat	16	380,65€	73.084,8€	
TAF+emtricitabine+darunavir/cobicistat	16	918€	176.256€	103.171,2€
TDF+emtricitabine+3 <sup>o</sup> drug (not studied)	37	31,2€	13.852,8€	
TAF+emtricitabine+3 <sup>o</sup> drug (not studied)	37	314,3€	139.549,2€	125.696,4€

## CONCLUSION

Almost 75% of patients with TDF used a treatment regimen with emtricitabine + elvitegravir.

Adherence to treatment was excellent.

The consideration to switch TDF to TAF must take into account its associated cost due to the high impact that would imply



**J05 - Antivirals for systemic use**

**2SPD-005**